Summary:

This presentation discusses forward-looking statements regarding our pipeline of novel therapeutics for metabolic and endocrine diseases, including VK2735 for obesity, VK2809 for NASH, and VK0214 for X-ALD. Key findings from recent clinical studies, including promising efficacy and safety data, are presented to highlight our strategic initiatives and future directions.